The North America Antibody Drug Conjugates Market would witness market growth of 13.7% CAGR during the forecast period (2022-2028).
ADCs are anticancer medications that are one of the quickest treatments for cancer patients, with the ability to use the selectivity of monoclonal antibodies against targeted antigens to release potentially lethal chemicals with enhanced activity and lower toxicity than chemotherapies. For cancer treatment, ADCs use antibodies as a vehicle to provide high-potency cytotoxic drug molecules to particular tumor-related antigens. The approval of ten ADCs, including Adcetris and Kadcyla, which are specific for Cd30 and HER2 antigen sites, respectively, demonstrates recent breakthroughs in ADC technology.
The overall share of people aged 65 and up will reach close to 16 percent by 2050. For example, according to the World Health Organization (WHO), by 2050, 80 percent of the world's elderly would be living in OECD countries. The impact of an ageing population on health care systems will be significant.
The antibody-drug conjugate industry in the region is extremely competitive, due to a large number of market players. The rising multiplication of technologically revolutionary technologies in nations such as Canada, the United States, and Mexico, this region is predicted to rapidly control the market. In terms of clinical data, North America is a relatively developed region, and the use of ADCs is considered and accounts for the vast bulk of the established market. Pfizer, for example, acquired Amplyx Pharmaceuticals in April 2021 to create antibody-drug conjugates and other cancer medicines.
For instance, according to the American Cancer Society, an estimated 2, 87,850 new cases of invasive breast cancer would be identified in women in the United States year 2020. In addition, 48,530 cases of in situ breast cancer in women have been investigated, with the number of malignant breast cases predicted to rise in the coming years. Over the forecast period, the growing cases of breast cancer and the existence of good healthcare infrastructure in the region are supposed to drive the antibody drug conjugates market's overall growth.
The US market dominated the North America Antibody Drug Conjugates Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,845 Million by 2028. The Canada market is experiencing a CAGR of 16.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 15.2% during (2022 - 2028).
Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Breast Cancer
- Blood Cancer
- Urothelial Cancer & Bladder Cancer
- Others
By Technology
- Cleavable Linker
- Non-Cleavable Linker
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Gilead Sciences, Inc.
- Seagen, Inc.
- ADC Therapeutics SA
- Daiichi Sankyo Company, Limited
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Antibody Drug Conjugates Market, by Application
1.4.2 North America Antibody Drug Conjugates Market, by Technology
1.4.3 North America Antibody Drug Conjugates Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition & mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
Chapter 4. North America Antibody Drug Conjugates Market by Application
4.1 North America Breast Cancer Market by Country
4.2 North America Blood Cancer Market by Country
4.3 North America Urothelial Cancer & Bladder Cancer Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Antibody Drug Conjugates Market by Technology
5.1 North America Cleavable Linker Market by Country
5.2 North America Non-Cleavable Linker Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Antibody Drug Conjugates Market by Country
6.1 US Antibody Drug Conjugates Market
6.1.1 US Antibody Drug Conjugates Market by Application
6.1.2 US Antibody Drug Conjugates Market by Technology
6.2 Canada Antibody Drug Conjugates Market
6.2.1 Canada Antibody Drug Conjugates Market by Application
6.2.2 Canada Antibody Drug Conjugates Market by Technology
6.3 Mexico Antibody Drug Conjugates Market
6.3.1 Mexico Antibody Drug Conjugates Market by Application
6.3.2 Mexico Antibody Drug Conjugates Market by Technology
6.4 Rest of North America Antibody Drug Conjugates Market
6.4.1 Rest of North America Antibody Drug Conjugates Market by Application
6.4.2 Rest of North America Antibody Drug Conjugates Market by Technology
Chapter 7. Company Profiles
7.1 Takeda Pharmaceutical Company Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.1 Recent strategies and developments:
7.1.1.1 Partnerships, Collaborations, and Agreements:
7.1.1.2 Acquisitions and Mergers:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 AstraZeneca PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 GlaxoSmithKline PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations and Agreements:
7.6 Astellas Pharma, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Approvals and Trials:
7.7 Gilead Sciences, Inc.
7.7.1 Company overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Acquisitions and Mergers:
7.7.4.2 Partnerships, Collaborations and Agreements:
7.8 Seagen, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.8.4 Recent strategies and developments:
7.8.4.1 Partnerships, Collaborations, and Agreements:
7.9 ADC Therapeutics SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Approvals and Trials:
7.10. Daiichi Sankyo Company, Limited
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expense
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:
TABLE 1 North America Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 2 North America Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Antibody Drug Conjugates Market
TABLE 4 Acquisition & mergers – Antibody Drug Conjugates Market
TABLE 5 Approvals and trials– Antibody Drug Conjugates Market
TABLE 6 North America Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 7 North America Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 8 North America Breast Cancer Market by Country, 2018 - 2021, USD Million
TABLE 9 North America Breast Cancer Market by Country, 2022 - 2028, USD Million
TABLE 10 North America Blood Cancer Market by Country, 2018 - 2021, USD Million
TABLE 11 North America Blood Cancer Market by Country, 2022 - 2028, USD Million
TABLE 12 North America Urothelial Cancer & Bladder Cancer Market by Country, 2018 - 2021, USD Million
TABLE 13 North America Urothelial Cancer & Bladder Cancer Market by Country, 2022 - 2028, USD Million
TABLE 14 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 15 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 16 North America Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 17 North America Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 18 North America Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 19 North America Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 20 North America Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 21 North America Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 22 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 23 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 24 North America Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
TABLE 25 North America Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
TABLE 26 US Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 27 US Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 28 US Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 29 US Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 30 US Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 31 US Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 32 Canada Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 33 Canada Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 34 Canada Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 35 Canada Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 36 Canada Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 37 Canada Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 38 Mexico Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 39 Mexico Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 40 Mexico Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 41 Mexico Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 42 Mexico Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 43 Mexico Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 44 Rest of North America Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 45 Rest of North America Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 46 Rest of North America Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 47 Rest of North America Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 48 Rest of North America Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 49 Rest of North America Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 50 Key Information – Takeda Pharmaceutical Company Limited
TABLE 51 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 52 KEY INFORMATION – ASTRAZENECA PLC
TABLE 53 Key Information – GlaxoSmithKline PLC
TABLE 54 Key Information – Pfizer, Inc.
TABLE 55 key information – Astellas Pharma, Inc.
TABLE 56 Key Information – Gilead Sciences, Inc.
TABLE 57 Key Information – Seagen Inc.
TABLE 58 Key Information – ADC Therapeutics SA
TABLE 59 Key Information – Daiichi Sankyo Company, Limited
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
FIG 5 Recent strategies and developments: Takeda Pharmaceutical Company Limited
FIG 6 Recent strategies and developments: Gilead Sciences, Inc.